Post-acute Sequelae of COVID-19 Case Fatality Rate and its Associated Covariates: A Systematic Review, Meta-Analysis and Meta-Regression

*John Muthuka K.1,2, Rosemary Nabaweesi3, Kelly Oluoch J.1, Japheth Nzioki M.4, and Charles Maibvise5

Affiliations: 1Kenya Medical Training College, Nairobi, Kenya; 2College of Health Sciences, KEMRI Graduate School, Nairobi, Kenya; 3Meharry Medical College, Nashville, TN, USA; 4Jumeira University, Dubai, United Arabs Emirates; 5University of Eswatini, Mbabane, Eswatini

*Corresponding author: Dr. John Muthuka K. Email: johnmuthuka@gmail.com

Received May 18, 2023
Accepted for publication on June 26, 2023
Published July 7, 2023

Abstract

Background. Long COVID is a wide range of new, returning, or ongoing health problems experienced after primary COVID-19 infection, with a possibility of broad adverse outcomes. The aim of this study was to determine the case fatality of of post-acute sequelae of COVID-19 (PASC) and assess possible covariates. Population and Methods. We conducted a systematic review and meta-analysis from 43 studies (367,236 patients), (June, 2020 - August, 2022). PASC mortality was assessed from six studies. With random-effects model, the pooled case fatality was measured. Publication bias was ascertained and meta-regression analysis done on predetermined covariates. Results. The estimated prevalence of PASC was 42.5% (95% CI = 36.0 % - 49.3%). The pooled case fatality was 7.4% (95% CI = 7.4% to 11.2%). The funnel plot suggested the presence of publication bias. Hospital re-admission (P = 0.0034) (R² = 1.00) and the year 2021 (P = 0.0309) (R² = 0.55) were associated with fatalities from PASC. Discussion. PASC increased the case-fatality of COVID-19, particularly during the year 2021, reflecting a longer follow-up of patients and with hospital re-admission. It is recommended to monitor patients re-admitted to hospital post index COVID-19 closely monitor specific clinical parameters that may increase the risk of death.

Keywords: Post-Acute COVID-19 Syndrome, Fatal Outcome, Prevalence, Meta-Analysis


Introduction

Despite several studies describing the case-fatality rate (CFR) of the novel coronavirus disease-2019 (COVID-19) [1-4], there is dearth of information on CFR among those meeting the definition of post-acute sequelae of COVID-19 (PASC). Further, reports have indicated vaccination against COVID-19 disease would mitigate the long-term effects [5,6] including fatalities associated with PASC. Studies have attempted to estimate the CFR in PASC [7-10], but the information is sparse.

PASC occurs in individuals with a history of probable or confirmed SARS CoV-2 infection, usually 3 months from the onset of COVID-19 with symptoms and that last for at least 2 months and cannot be explained by an alternative diagnosis. Common symptoms of PASC include fatigue, shortness of breath, and cognitive dysfunction among others. Symptoms
may be new onset following initial recovery from an acute COVID-19 episode or persist from the initial illness. Symptoms may also fluctuate or relapse over time [11].

PASC is a syndrome characterized by the persistence of clinical symptoms beyond four weeks from the onset of acute symptoms. The Center for Disease Control (CDC) has formulated "post-COVID-19 conditions" to describe health issues that persist more than four weeks after being infected with COVID-19 [12]. Recent reports have described persistent symptoms extending beyond the period of initial illness or hospitalization. Anecdotes of different signs and symptoms occurring after acute infection have also arisen in the lay press [13]. Pulmonary, neuro-psychological, and cardiovascular complications are major findings in most epidemiological studies. However, dysfunctional gastrointestinal, endocrine, and metabolic health are recent findings for which underlying pathophysiological mechanisms are poorly understood [14].

The multisystem nature of PASC compared to previously studied post-acute sequelae of human coronaviruses has raised questions about how to recognize this condition most effectively [15]. Furthermore, regardless of whether they are unique, symptoms frequently reported by patients are not assessed consistently across studies [16]. Based on limited data from multiple studies, patients with PASC who required admission to the intensive care unit and/or ventilatory support were shown to be at increased risk of developing the syndrome [12].

People who have more severe COVID-19 are more likely to experience PASC, but severe acute disease is not a prerequisite. PASC has been found in people with only mild initial illness. The most common symptom is fatigue [17]. More than 6 million people have died from COVID-19 worldwide, including nearly 1 million in the USA [18]. But mortality is not the only adverse consequence of COVID-19. Many survivors of COVID-19 may develop PASC often calls long COVID [17], and presumed to be fatal [19].

People with a history of severe COVID-19 illness are at increased risk of PASC and possible associated death [20]. From January 1, 2020, through June 30, 2022, in United States of America alone, 3,544 COVID-19 deaths mentioned PASC in the death certificate, representing 0.3% of the 1,021,487 deaths with COVID-19 coded to U07.1 (the ICD–10 code for COVID-19) as an underlying or contributing cause of death in the same time period as per the Vital Statistics Rapid Release.

The purpose of this review was to estimate the reported prevalence of PASC and its associated CFR. Further, it explored covariates that would influence the fatality.

Population and Methods

Search Strategy

A systematic search had been performed using the online databases of PubMed, Science Direct and Google Scholar databases of PubMed, Science Direct and Google Scholar.
Statistical Analysis

Simple descriptive analyses were performed for the aims of the review. Heterogeneity among the studies was assessed using the chi-squared test and test of heterogeneity (I²), however due to suspected variation among the studies and associated heterogeneity random effects models were used for all meta-analyses [25]. PASC events rates were estimated using random-effects model, the estimation of the occurrence of deaths among patients with PASC was statistically assessed using random effects models (DerSimonian and Laird) [26], and event rates were presented. Publication bias was assessed using the Begg and Mazumdar Rank Correlation Test and the Egger's Test of the Intercept and a precision funnel plot was used to ascertain this the publication bias status. To account for any possible heterogeneity, sub-group and sensitivity analysis were conducted and in this, some analysis used fixed-effect model analysis, further to these, meta-regression analysis was run for year of publication, hospital re-admission, the study design, the study setting and the region a study as pre-determined covariates. For each outcome variable, 95% confidence intervals (CIs) were presented. A P-value < 0.05 was considered statistically significant.

Results

There were 2,197 articles identified in the initial search of databases and reference lists. After initial screening of titles and abstracts 197 articles met the inclusion criteria for review. On full text screening, the number reduced to 57 studies. Further, 14 studies without clinical outcomes were eliminated as shown in Figure 1, which displays the PRISMA flow diagram.

The studies that met the inclusion criteria on PASC from where six studies detailing mortality outcome were retrieved are shown in the Table 1.

Figure 1. PRISMA flow diagram showing studies identified and included in a systematic meta-analysis
Table 1. Summary of the studies used in the analysis of the prevalence and case-fatality of Post-Acute Sequelae of COVID-19, 2020-2022

<table>
<thead>
<tr>
<th>Reference #</th>
<th>Continents</th>
<th>Type of Case Series</th>
<th>Study Setting</th>
<th>Average time to PASC diagnosis (months)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1.</td>
<td>27 Africa</td>
<td>Prospective</td>
<td>Single</td>
<td>2</td>
</tr>
<tr>
<td>2.</td>
<td>65 Europe</td>
<td>Prospective</td>
<td>Single</td>
<td>3</td>
</tr>
<tr>
<td>3.</td>
<td>28 Europe</td>
<td>Retrospective</td>
<td>Multicenter</td>
<td>5</td>
</tr>
<tr>
<td>4.</td>
<td>29 America</td>
<td>Prospective</td>
<td>Multicenter</td>
<td>2</td>
</tr>
<tr>
<td>5.</td>
<td>30 Europe</td>
<td>Prospective</td>
<td>Single</td>
<td>6</td>
</tr>
<tr>
<td>6.</td>
<td>31 Europe</td>
<td>Prospective</td>
<td>Multicenter</td>
<td>12</td>
</tr>
<tr>
<td>7.</td>
<td>32 Asia</td>
<td>Prospective</td>
<td>Single</td>
<td>6</td>
</tr>
<tr>
<td>8.</td>
<td>33 Europe</td>
<td>Prospective</td>
<td>Multicenter</td>
<td>12</td>
</tr>
<tr>
<td>9.</td>
<td>34 Africa</td>
<td>Prospective</td>
<td>Single</td>
<td>3</td>
</tr>
<tr>
<td>10.</td>
<td>35 Asia</td>
<td>Retrospective</td>
<td>Single</td>
<td>9</td>
</tr>
<tr>
<td>11.</td>
<td>36 Europe</td>
<td>Cross sectional</td>
<td>Single</td>
<td>11</td>
</tr>
<tr>
<td>12.</td>
<td>37 Asia</td>
<td>Retrospective</td>
<td>Single</td>
<td>-</td>
</tr>
<tr>
<td>13.</td>
<td>38* America</td>
<td>Prospective</td>
<td>Single</td>
<td>4</td>
</tr>
<tr>
<td>14.</td>
<td>39* Europe</td>
<td>Retrospective</td>
<td>Multicenter</td>
<td>6</td>
</tr>
<tr>
<td>15.</td>
<td>40 America</td>
<td>Retrospective</td>
<td>Multicenter</td>
<td>1</td>
</tr>
<tr>
<td>16.</td>
<td>41 Asia</td>
<td>Prospective</td>
<td>Multicenter</td>
<td>3</td>
</tr>
<tr>
<td>17.</td>
<td>42 Asia</td>
<td>Cross sectional</td>
<td>Multicenter</td>
<td>3</td>
</tr>
<tr>
<td>18.</td>
<td>43* America</td>
<td>Prospective</td>
<td>Single</td>
<td>-</td>
</tr>
<tr>
<td>19.</td>
<td>44 America</td>
<td>Prospective</td>
<td>Single</td>
<td>6</td>
</tr>
<tr>
<td>20.</td>
<td>46 Europe</td>
<td>Cross sectional</td>
<td>Single</td>
<td>-</td>
</tr>
<tr>
<td>21.</td>
<td>5* Europe</td>
<td>Retrospective</td>
<td>Single</td>
<td>12</td>
</tr>
<tr>
<td>22.</td>
<td>45 Asia</td>
<td>Prospective</td>
<td>Single</td>
<td>-</td>
</tr>
<tr>
<td>23.</td>
<td>46 Europe</td>
<td>Prospective</td>
<td>Multicenter</td>
<td>7</td>
</tr>
<tr>
<td>24.</td>
<td>47 Europe</td>
<td>Prospective</td>
<td>Multicenter</td>
<td>3</td>
</tr>
<tr>
<td>25.</td>
<td>48 Europe</td>
<td>Prospective</td>
<td>Single</td>
<td>1</td>
</tr>
<tr>
<td>26.</td>
<td>49 Asia</td>
<td>Prospective</td>
<td>Single</td>
<td>-</td>
</tr>
<tr>
<td>27.</td>
<td>50 Africa</td>
<td>Retrospective</td>
<td>Single</td>
<td>5</td>
</tr>
<tr>
<td>28.</td>
<td>51 Africa</td>
<td>Retrospective</td>
<td>Single</td>
<td>5</td>
</tr>
<tr>
<td>29.</td>
<td>52 Asia</td>
<td>Prospective</td>
<td>Single</td>
<td>-</td>
</tr>
<tr>
<td>30.</td>
<td>53 Europe</td>
<td>Bidirectional</td>
<td>Single</td>
<td>6</td>
</tr>
<tr>
<td>31.</td>
<td>67 Europe</td>
<td>Cross sectional</td>
<td>Single</td>
<td>7</td>
</tr>
<tr>
<td>32.</td>
<td>54 America</td>
<td>Retrospective</td>
<td>Multicenter</td>
<td>5</td>
</tr>
<tr>
<td>33.</td>
<td>55 Europe</td>
<td>Prospective</td>
<td>Single</td>
<td>4</td>
</tr>
<tr>
<td>34.</td>
<td>64* Europe</td>
<td>Retrospective</td>
<td>Multicenter</td>
<td>4</td>
</tr>
<tr>
<td>35.</td>
<td>68 Asia</td>
<td>Prospective</td>
<td>Single</td>
<td>3</td>
</tr>
<tr>
<td>36.</td>
<td>56* Europe</td>
<td>Prospective</td>
<td>Multicenter</td>
<td>3</td>
</tr>
<tr>
<td>37.</td>
<td>57 America</td>
<td>Retrospective</td>
<td>Single</td>
<td>-</td>
</tr>
<tr>
<td>38.</td>
<td>58 America</td>
<td>Retrospective</td>
<td>Multicenter</td>
<td>6</td>
</tr>
<tr>
<td>39.</td>
<td>59 Asia</td>
<td>Cross sectional</td>
<td>Single</td>
<td>4</td>
</tr>
<tr>
<td>40.</td>
<td>60 Europe</td>
<td>Prospective</td>
<td>Single</td>
<td>3</td>
</tr>
<tr>
<td>41.</td>
<td>61 America</td>
<td>Prospective</td>
<td>Multicenter</td>
<td>-</td>
</tr>
<tr>
<td>42.</td>
<td>62 Europe</td>
<td>Prospective</td>
<td>Single</td>
<td>3</td>
</tr>
<tr>
<td>43.</td>
<td>63 Europe</td>
<td>Retrospective</td>
<td>Single</td>
<td>9</td>
</tr>
</tbody>
</table>

*Indicates the study provided detailed information on deaths due to PASC
Prevalence estimates of PASC and associated case-fatality rate in general population

The prevalence of PASC was 42.5% from total of 43 studies [5, 27-29, 31-68], (n = 367,236) [42.5% (95% CI 36.0% to 49.3%)] with a prediction interval of 10.5% to 82.3% [Heterogeneity: \( \tau^2 = 0.81 \); \( \text{Chi}^2 = 24108.789, \text{df} = 42 (P = 0.03) \); \( I^2 = 100\% \)] (Figure 1).

PASC case-fatality rate

From the 43 studies detailing PASC in general population, six studies [5, 23, 38-39, 43, 57] representing 61,977 cases of PASC on which detailed mortality was reported: the summary estimate was 7.4% (95% CI 4.9%, 11.2%) [Heterogeneity: \( \tau^2 = 0.258 \); \( \text{Chi}^2 = 228.174, \text{df} = 5 (P < 0.001) ; I^2 = 97.8\% \)]. Following sensitivity analysis with one study removed [28], it sustained the same CFR at 7.4% (Figure 2).

Figure 1. Figure 2. Post Acute Sequelae of COVID-19 Case Fatality in Six Studies 2020-2021
The prediction interval in 95% of all the study populations for the CFR due to PASC was at one extreme as low as 2.0% and as high as 28.0%.

The inspection of the precision plot shows a deficit of small studies (that is with a larger standard error, hence a lower reciprocal of it) on the right side of the plot (Figure 3). The Begg and Mazumdar Rank Correlation Test (Kendall’s tau b = 0.0000, P-value = 0.5000) does not indicate the presence of publication bias, although the Egger’s Test of the Intercept (Intercept = -4.78903, 95% confidence interval (-13.00383, 3.42577), with t=1.61860, df=4. P-value = 0.09 suggests some degree of asymmetry, hence evidence of publication bias.
**Meta-regression analysis**

For the substantial heterogeneity, meta-regression analysis was conducted including the year a study was conducted, hospital re-admission, the study design, the study setting and the region a study was conducted as the data on covariates available, which would allow us to assess whether and which study-level factors drove these estimates. This meta-regression analysis featured as per the objectives of this meta-analysis on the CFR among PASC diagnosed patients. PASC related mortality was significantly and perfectly correlated with hospital re-admission following meta-regression analysis ($Q = 8.58, df = 1, P = 0.003$) ($R^2$ analog = 1.00). Further, studies conducted in the year 2021 as opposed to the year 2020 were significantly associated with PASC related CFR at 55.0 % ($Q = 4.66, df = 1, P = 0.03$) ($R^2$ analog = 0.55).

**Discussion**

This review, meta-analysis and meta-regression found that across studies, the prevalence of PASC was 42.5% (95% CI = 36.0 % to 49.3%) ranging between 1.6% (lowest) to 82.0% (highest) event rate of PASC in the 43 studies in this current study. Our pooled point estimate of the prevalence of PASC was similar to that of another meta-analysis (43.0% [95% CI: 39.0 %, 46.0%]) [69], while a primary study found demonstrate that the prevalence of long-COVID was 43.6% [70].

CFR from PASC was 7.4%, and although the range of variation (4.9% to 11.2%) might reflect differences in real proportions, our estimate was very consistent with findings relative to PASC CFR across different time-points during the 30 days, 90 days and one-year post-discharge, 7.9%, 7.3%, and 7.1% respectively. The 30-day hospital and further post discharge CFR was 7.9% [71]. This finding was, however, lower than that of one other single study which reported a CFR of 19.0% over 12 months [20].

PASC CFR correlated with hospital readmission. Most hospital readmissions fatalities seem to occur within 30 days after discharge [71], but this may be due to the limited follow-up, as studies with a longer follow-up have found that, COVID-19 patients were more likely to be readmitted or die due to their initial infection (adjusted hazard ratio of 1.4; 95% CI = 1.2 to 1.5, $P < 0.001$) [72-73]. Studies conducted in the year 2021 were strongly correlated with PASC fatality (i.e., explained variance of 55.0 %), which may just reflect a longer follow-up time, and a larger pool of infected persons, at least one year after the onset of infection [21].

A limitation of the current review was the definition of inclusion criteria for a PASC patient, presenting with either one or more suspected signs or symptoms depicting the syndrome, however, a WHO clinical case definition of post COVID-19 condition by a Delphi consensus, 6 October 2021 [11, 74], was used as a guide. Only six studies retrieved detailed PASC deaths and were the only available at the time of this review. The selection process of the studies included in this review was narrowed to those which only had detailed mortality outcome relative to the PASC which prevented a broad inclusion of all the 43 studies detailing the PASC. Further, another limitation of the review consisted of restricting the studies to those published in English only. However, as at the time of the review, we were unaware of reports published in on other languages. There is some evidence of absence of small studies with estimates of CFR above 12% (i.e., right side of the funnel plot).

The implications for health policy from this study are significant even if the COVID-19 pandemic has ended: the large number of persons affected calls for a continued review of the clinical practice and management of PASC. Further, the study adds new knowledge on CFR due to PASC.

**References**


10. Figueiredo C de S, Giacomin KC, Gual RF, de Almeida SC, Assis MG. Death and Other Losses in the COVID-19 Pandemic in Long-Term Care Facilities for Older Adults in the Perception of Occupational Therapists: A Qualitative Study. *Omega (United States)*. Published online 2022. doi:10.1177/00302228221086169


71. Ramzi ZS. Hospital readmissions and post-discharge all-cause mortality in COVID-19 recovered patients; A

